Novartis (Brazil) Today
| N1VS34 Stock | BRL 67.05 0.40 0.59% |
PerformanceOK
| Odds Of DistressLow
|
Novartis is trading at 67.05 as of the 16th of March 2025, a 0.59 percent decrease since the beginning of the trading day. The stock's open price was 67.45. Novartis has less than a 9 % chance of experiencing financial distress in the next few years and had a ok performance during the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was founded in 1895 and is headquartered in Basel, Switzerland. NOVARTIS operates under Drug ManufacturersGeneral classification in Brazil and is traded on Sao Paolo Stock Exchange. The company has 2.12 B outstanding shares. More on Novartis AG
Moving against Novartis Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Novartis Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Novartis' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Novartis or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers—General, Healthcare (View all Sectors) |
Novartis AG (N1VS34) is traded on Sao Paulo Exchange in Brazil and employs 102,000 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 970.05 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novartis's market, we take the total number of its shares issued and multiply it by Novartis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novartis AG operates under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 2.12 B outstanding shares.
Novartis AG has accumulated about 10.69 B in cash with 15.07 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.7.
Check Novartis Probability Of Bankruptcy
Novartis AG Risk Profiles
Although Novartis' alpha and beta are two of the key measurements used to evaluate Novartis' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.73 | |||
| Semi Deviation | 1.82 | |||
| Standard Deviation | 2.19 | |||
| Variance | 4.78 |
Novartis Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novartis without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
Novartis Corporate Management
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Saynor | Chief Sandoz | Profile | |
| Steffen Lang | Pres Operations | Profile | |
| MarieFrance Tschudin | Pres Officer | Profile | |
| Paul Penepent | Head Accounting | Profile | |
| Samir MD | Global Relations | Profile | |
| Robert PharmD | Chief Officer | Profile | |
| Klaus Moosmayer | Risk Ethics | Profile |
Other Information on Investing in Novartis Stock
Novartis financial ratios help investors to determine whether Novartis Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novartis with respect to the benefits of owning Novartis security.